

TOPIC: Healthcare Provider Conference 2008: Collaboration for Advancing the Quality of Community Cancer Care EM 1300
DATE: April 15, 2009 – Release date

SPEAKERS: Jill Kolesar, PharmD, BCPS, FCCP, RPhKaren Pilley, CPC, CCS-P, Mary Ann K. Allison, MD, FACP, Roy A. Beveridge, MD, Sami Diab, MD, Joan Engebretson, DrPH, AHN-BC, RN, Michael Forsyth, RPh, MBA Moshe Frenkel, MD, Patty Gerken, ANP-BC, AOCN, Ka-Kit Hui, MD, FACP

LOCATION: Enduring Material
OBJECTIVES:

1. Evaluate the current and future potential applications of epigenetics to drug therapy
2. Incorporate current data on the safety and efficacy of new treatment options for the treatment of patients with genitourinary cancer
3. Outline the indication, mechanism of action, and safety profile of new drugs utilized in the treatment of hematologic disorders and solid tumors
4. Manage the current and future reimbursement and regulatory challenges that impact delivery of cancer care
5. Translate the recent advances in breast cancer management into current practice
6. Explain and discuss the basic principles of bone marrow transplantation with cancer patients
7. Summarize how integrative medicine is being utilized for cancer patients
8. Attend to patients' emotional, spiritual, and cultural needs throughout the course of their care
9. Utilize complementary therapies that can effectively increase patients' feeling of physical well-being
10. Discuss the impact of Chinese medicine on the well-being of cancer patients
11. List solutions to common problems faced by community cancer caregivers when establishing integrative care programs in their practice

DISCLOSURE:

Dr. Kolesar receives grant support from AstraZeneca and is a major stockholder for Helix Diagnostics. Dr. Forsyth is a consultant and on the Advisory Board for Sanofi-Aventis. Drs. Pilley, Allison, Beveridge, Diab, Engebretson, Frenkel, Gerken, and Hui have nothing to disclose.

Accreditation:
CME - This activity has been planned and implemented in accordance with the essential areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Texas Medical Branch at Galveston (UTMB) and Oncology Today™. The University of Texas Medical Branch at Galveston is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

 The University of Texas Medical Branch at Galveston designates this education activity for a maximum of 3 *AMA PRA Category 1 Credits*™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CNE 3.0 - The University of Texas Health Science Center at Houston School of Nursing is an approved provider of continuing nursing education by the Texas Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

ACPE - The University of Houston College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing education. Pharmacists documenting completion of the program "Healthcare Provider Conference 2008: Collaboration for Advancing the Quality of Community Cancer Care (# 066-999-09-003-H01-P) by signing in, completing evaluations and a post-test survey will receive 3 contact hour (0.3 CEU) pharmacy continuing education credit, and will receive a statement of credit by mail within 3 weeks of UHCOP being notified of the completion date. This is a Knowledge-Based Activity Initial Release Date: April 15, 2009 Expiration Date: April 14, 2012


First Name

MI

Last Name

Title
Address: _____

City: _____ **State:** _____ **Zip:** _____

Phone: _____

Fax: _____

Email: _____

PLEASE COMPLETE EVALUATION FORM BEFORE RETURNING

- Make solid marks that fill the response completely.
- Make no stray marks on this form.

Scale: 1= Strongly Disagree 2= Disagree 3= Agree 4= Strongly Agree

1	2	3	4	
(1)	(2)	(3)	(4)	The content of this presentation is applicable to my professional development.
(1)	(2)	(3)	(4)	The course objectives were met.
(1)	(2)	(3)	(4)	The presentation was clear and understandable.
(1)	(2)	(3)	(4)	The program was free of commercial bias and presented in an objective manner.
(1)	(2)	(3)	(4)	The presentation was scientifically based and accurate.
(1)	(2)	(3)	(4)	As a result of this course, my professional effectiveness will increase.

Disagree ← → Agree

Comments for strengths and improvements: _____

Title of Education Activity: Healthcare Provider Conference 2008: Collaboration for Advancing the Quality of Community Cancer Care

Location: Enduring Material Date: April 15, 2009 – Release Date

Purpose of this activity: Oncology research and treatment are constantly evolving and staying current with advances in the field is a significant challenge for community-based oncology nurses, pharmacists, physician assistants and other oncology clinicians. Furthermore, oncology healthcare providers are required to master an extensive spectrum of issues ranging from utilizing integrative medicine, implementing current advances in breast cancer, genitourinary cancers, and bone marrow transplantation into clinical practice, sensitive psychosocial concerns, as well as reimbursement and regulatory issues.

Through effective collaboration of both academic and community-based experts, an educational curriculum has been developed to integrate the most recent data with practical clinical application. Accordingly, the ultimate goal of this meeting is to improve cancer care quality and enhance patient outcomes in the community practice.

Please complete this evaluation questionnaire. Your anonymous responses will be used to revise this activity and to plan future educational activities. Circle the number that best fits your evaluation of this activity.

1 = Not at all 2 = Somewhat 3 = Almost completely 4 = Completely

1. Rate your achievement of these objectives:

- | | | | | |
|---|---|---|---|---|
| a. Evaluate the current and future potential applications of epigenetics to drug therapy | 1 | 2 | 3 | 4 |
| b. Incorporate current data on the safety and efficacy of new treatment options for the treatment of patients with genitourinary cancer | 1 | 2 | 3 | 4 |
| c. Outline the indication, mechanism of action, and safety profile of new drugs utilized in the treatment of hematologic disorders and solid tumors | 1 | 2 | 3 | 4 |
| d. Manage the current and future reimbursement and regulatory challenges that impact delivery of cancer care | 1 | 2 | 3 | 4 |
| e. Translate the recent advances in breast cancer management into current practice | 1 | 2 | 3 | 4 |
| f. Explain and discuss the basic principles of bone marrow transplantation with cancer patients | 1 | 2 | 3 | 4 |
| g. Summarize how integrative medicine is being utilized for cancer patients | 1 | 2 | 3 | 4 |
| h. Attend to patients' emotional, spiritual, and cultural needs throughout the course of their care | 1 | 2 | 3 | 4 |
| i. Utilize complementary therapies that can effectively increase patients' feeling of physical well-being | 1 | 2 | 3 | 4 |
| j. Discuss the impact of Chinese medicine on the well-being of cancer patients | 1 | 2 | 3 | 4 |
| k. List solutions to common problems faced by community cancer caregivers when establishing integrative care programs in their practice | 1 | 2 | 3 | 4 |

2. Rate the effectiveness of the teaching/learning resources? 1 2 3 4

3. Rate the expertise/effectiveness of each individual presenter?

- | | | | | |
|---------------------------------------|---|---|---|---|
| Jill Kolesar, PharmD, BCPS, FCCP, RPh | 1 | 2 | 3 | 4 |
| Karen Pilley, CPC, CCS-P | 1 | 2 | 3 | 4 |
| Mary Ann K. Allison, MD, FACP | 1 | 2 | 3 | 4 |
| Roy A. Beveridge, MD | 1 | 2 | 3 | 4 |
| Sami Diab, MD | 1 | 2 | 3 | 4 |
| Joan Engebretson, DrPH, AHN-BC, RN | 1 | 2 | 3 | 4 |
| Michael Forsyth, RPh, MBA | 1 | 2 | 3 | 4 |
| Moshe Frenkel, MD | 1 | 2 | 3 | 4 |

4. Were the objectives relevant to the overall purpose? 1 2 3 4

5. How long in minutes did it take you, learner to complete the activity? _____

6. List two (2) ways you will integrate what you learned in this activity into your practice and/or employment environment.

7. The following were disclosed prior to the beginning of this activity either in writing or verbally?

- | | | |
|---|-----|----|
| a. Requirements for successful completion | Yes | No |
| b. Conflicts of Interest | Yes | No |
| c. Commercial Support | Yes | No |
| d. Non-endorsement of Products | Yes | No |
| e. Off-label Use | Yes | No |
-

8. Did you, as a participant, notice any bias that was not previously disclosed in this presentation? Yes No
If "Yes", please describe who was biased and how.

Comments: (If you answered (1) to any of the above, please comment.)

You may ask additional questions, i.e., more information to identify future topics, as you desire.

Healthcare Provider conference 2008: Collaboration for Advancing the Quality of Community Cancer Care
Enduring Material
POST-TEST

Module I

New Drugs & Indications: Focus on Hematologic Disorders and Solid Tumors

Jill M. Kolesar, PharmD, BCPS, FCCP

1. CC is a 56 year old female with chronic ITP being treated with romiplostim at a dose of 2mcg/kg. Her platelet count today is 600 x 10⁹/L (600,000). What should you do?
 - a. Increase dose to 4mcg/kg
 - b. Tell her she is doing great and schedule another appt for 2 weeks
 - c. Stop romiplostin
 - d. None of the above

Module II

Reimbursement in the Oncology Practice: 2008 Update and Audience Case Challenges

Karen Pilley, CPC, CCS-P

2. How often should clinicians review charge capture to ensure all drug, drug administration and services are accounted for:
 - a. Daily
 - b. Weekly
 - c. Monthly
 - d. None of the above

Module III

Breast Cancer: Implementing Advances into Practice

Mary Ann K. Allison, MD, FACP

3. Based on The Star Trial, raloxifene is shown to be as effective as tamoxifen in the prevention of primary breast cancer
 - a. True
 - b. False

Module IV

Bone Marrow Transplantation: The Basics

Roy Beveridge, MD

4. BMT can cure:
 - a. Leukemia
 - b. Lymphoma
 - c. Myeloma
 - d. Genetic diseases
 - e. All of the above

Module V

Integrative Medicine and Community Cancer Care: Putting it into Practice

Moshe Frenkel, MD, Joan Engebretson, Dr PH, AHN-BC, RN, Sami Diab, MD, Ka-Kit Hui, MD, FACP

5. What percent of patients on chemotherapy have increased depression?
 - a. 5%
 - b. 21%
 - c. 61%
 - d. 99%
 - e. None of the above
6. Cancer specific uses of Complementary/Alternative Medicine (CAM) include reduction of side effects and organ toxicity, protection and stimulation of the immune system, prevention of recurrence, and assisting patients to cope with illness experience.
 - a. True
 - b. False
7. Unlike medications approved by the FDA, herbal products:
 - a. Are not required to prove claims of safety or effectiveness
 - b. Are not required to enforce quality control
 - c. Vary tremendously in concentration of active ingredients
 - d. All the above
8. The therapeutic goals of Traditional Chinese Medicine (TCM) include:
 - a. Restoring normal balance and flow
 - b. Individualization
 - c. Focus on enhancing the body's endogenous resistance (homeostatic reserve) to disease
 - d. Less emphasis on specific causal factors
 - e. All of the above